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ABSTRACT 
 
Canavan disease (CD) is an autosomal recessive disorder, characterized by spongiform 
degeneration of the white matter of the brain. Aspartoacylase (ASPA) hydrolyses N-
acetylaspartic acid to aspartate and acetate. Mutation of the gene results in enzyme 
deficiency to result CD. The clinical features seen in the disease are head lag, 
macrocephaly, hypotonia and mental retardation. More than forty five mutations have 
been identified in the ASPA gene. Pathophysiological abnormalities seen in CD is likely 
due to abnormal metabolic levels of NAA, aspartate, acetate, aspartate aminotransferase, 
glutamate, glutamate dehydrogenase, γ-aminobutyric acid, and ketoglutarate 
dehydrogenase complex.  These pathways are useful to understand possible therapeutical 
targets and pharmacological manipulations in CD. 
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INTRODUCTION 
 
Canavan disease (CD) is a 
neurodegenerative disorder. 
Aspartoacylase/aminoacylase II (ASPA; 
EC 3.5.1.15) hydrolyses N-acetylaspartic 
acid (NAA) to aspartate and acetate 
(Birnbaum, 1955; Birnbaum et al., 1952). 
Aspartoacylase gene has been mapped to 
the 17p13-ter region (Kaul et al., 1993; 
1994a). ASPA activity is mainly present in 
brain and kidney (Kaul et al., 1993). ASPA 
has a vital role in the compartmentalization 
of NAA in brain. While neurons are rich in 
NAA (Jacobson, 1957; Birken et al., 1989; 
Moffett et al., 1991; Baslow et al., 1997), 
ASPA is predominantly found in 
oligodendrocytes (Baslow et al., 1999). 
ASPA mutation (Kaul et al., 1993) 
resulting enzyme deficiency (Matalon et 
al., 1988) leads to CD (Globus and Strauss, 
1928; Canavan, 1931; van Bogaert and 
Bertrand, 1949; Adachi et al., 1972; 
Adornato et al., 1972). The clinical 
features of the disease include 
psychomotor retardation, megalencephaly 
and hypotonia (van Bogaert and Bertrand, 
1949). The brain of the patient showed 
swollen astrocytes and elongated 
mitochondria (Globus and Strauss, 1928; 
Canavan, 1931; van Bogaert and Bertrand, 
1949; Adachi et al., 1972; Adornato et al., 
1972). Although CD is pan ethnic, the 
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disease is more prevalent in Ashkenazi 
Jewish population. 
 
An ASPA knockout mouse (Matalon et al., 
2000) and a tremor rat (Kitada et al., 2000; 
Seki et al., 2004) are available to study 
molecular mechanism involved in CD. 
These animal models showed ASPA 
deficiency, NAA accumulation and 
spongiform degeneration in the brain 
(Kitada et al., 2000; Seki et al., 2004).  
Aspartoacylase deficiency in the mouse 
induced vacuolation not only in the white 
matter of the brain but also at all levels of 
the spinal cord (Surendran et al., 2005). 
These animal models are useful to 
understand molecular events involved in 
CD. 
 
Therapeutical attempts are being made to 
recover the lost enzyme as well as the lost 
function in CD. Aspartoacylase gene 
transfer to the brain improved 
neurodegeneration close to the injection 
site (Matalon et al., 2003; Leone et al., 
2004; McPhee et al., 2005). Implantation 
of neural progenitor cells to the mouse 
brain differentiated into oligodendrocytes 
(Surendran et al., 2004a). Whether therapy 
affects all the events seen in CD is yet to 
be studied. 
 
Clinical symptoms of CD 
Infants with CD show mild delays, 
hypotonia, and inadequate visual tracking. 
These infants become progressively 
irritable, and remain hypotonic with poor 
head control (Matalon et al., 1989). 
Developmental delay and larger head are 
visible after 6 months of age. Patients can 
not sit, stand, walk or talk. Children with 
CD develop optic atrophy and have 
difficulty focusing, but are able to 
recognize their surroundings. Feeding 
difficulties increase with age, and feeding 
by a nasogastric tube or permanent 
gastrostomy will be needed. 
 
Aspartoacylase gene 
Aspartoacylase gene was located in the 
short arm of chromosome 17 (17p13-ter) 
(Kaul et al., 1993; 1994a).  The human 
ASPA gene spans about 29 kb of DNA, 
with 6 exons and 5 introns. Human ASPA 
complementary DNA (cDNA) contains 
1,435 base pairs that encode 313 
aminoacids (Kaul et al., 1993; 1994b), an 
enzyme with a molecular weight of 
approximately 37 kDa. The enzyme 
converts NAA into aspartate and acetate 
(Fig 1). There have been over 45 mutations 
identified in the human ASPA gene. The 
genomic organization of the gene with 
various mutations is shown in Table 1. The 
deduced amino acid sequence of mouse 
ASPA is 86% identical and 94% similar to 
that of human ASPA and the catalytic 
domains are 100% identical (Namboodiri 
et al., 2000). The fifth aminoacid seen in 
human ASPA protein “H” (histidine) is not 
present in the mouse protein. Hence, 
mouse ASPA cDNA encodes 312 
aminoacids. 
 
The two common mutations, E285A and 
Y231X that account for over 76% of the 
mutations among Azhkenazi Jewish 
population (Kaul et al., 1993). The most 
common non-Jewish mutation is A305E 
(Kaul et al., 1994b).  Mutation D114Y was 
found in a small geographical region in 
Norway and D249V mutations was 
specific to Norwegian and Swedish 
population (Olsen et al., 2002) suggesting 
some mutations in ASPA gene are founder 
mutations. 
 
 
 
 78
 
 
Figure 1: N-acetylaspartic acid is hydrolyzed into L-aspartic acid and acetate by 
aspartoacylase (ASPA), the enzyme deficient in CD. 
 
Exon 1 
 
 
 
I16T,  
E24G, 
G27R, 
D68A, 
10T>G, 
11insG, 
32delT,  
33del13bp 
 
 
 
 
 
 
Exon2  
 
 
 
Y109X, 
D114E,  
D114Y, 
G123E, 
I143T,  
244delA, 
245insA, 
IVS1 -
2A>T 
 
 
Exon 3 
 
 
 
C152R, 
C152Y, 
C152W, 
R168C, 
IVS2 del-
2A, -3C 
 
 
Exon4 
 
 
 
P181T,  
P183H, 
Q184X, 
V186F, 
M195R, 
527 
del6bp, 
566del7bp 
 
 
Exon5 
 
 
 
K213E 
E214X, 
C218X, 
Y231X, 
H244R,  
D249V 
698insC, 
635del10bp 
 
 
Exon6 
 
 
 
G274R,  
P280S, 
P280L, 
E285A, 
A287T, 
Y288C, 
F295S, 
X314W, 
827delGT, 
870del4bp, 
876del4bp, 
923delT 
 
 
Table 1: Sketch of Aspartoacylase with five introns and six exons. The human 
ASPA gene spans 29Kb. Mutations E285A and Y231X are common in Jewish 
population. The A305E mutation is coomon in European population, the C218X 
mutation is found in Gypsy population, the D249V mutation is identified in 
Norwegian and Swedish populations and the D114Y mutation is identified in 
region specific Norwegian CD patients. 
 
The Y288C variant (Surendran et al., 
2003a; Tacke et al., 2005) does not result 
in all the events seen in classical CD and 
therefore this mutation may be classified as 
mild CD. Preimplantation genetic 
diagnosis (PGD) using a single-cell nested 
PCR approach (Yaron et al., 2005 ) helps 
to identify embryos with CD and therefore 
CD birth may be prevented. 
 
NAA metabolism in the brain of CD 
N-acetylaspartic acid, the substrate for 
ASPA is synthesized from acetyl-
coenzyme A and aspartate by L-aspartate 
N-acetyltransferase (Goldstein, 1976), 
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located in the mitochondria of the brain 
(Patel and Clark, 1979; Bates et al., 1996). 
NAA may be involved in osmotic 
regulation, neuromodulation and 
lipogenesis during myelination (Birken and 
Oldendorf, 1989). NAA level is three times 
higher in the brain of CD (Grodd et al., 
1990; Wittsack et al., 1996). The 
accumulation of NAA in the brain leads to 
approximately 50 times higher urinary 
NAA. NAA-derived acetate is a major 
source for the synthesis of fatty acids/lipids 
used for myelination (Kirmani et al., 2003; 
Madhavarao et al., 2004) and therefore 
reduced level of acetate seen in CD is 
likely to contribute to neurodegeneration. 
 
Neuropathology in the brain of CD 
Aspartoacylase deficiency resulting NAA 
metabolism affects the brain. The 
concentration of NAA in the human fetus 
brain in utero is approximately 2.5μmol/g 
(Kato et al., 1997), while in the normal 
adult human brain the level varies 8-10 
μmol/g (Frahm et al., 1989; Kreis et al., 
1993). Nuclear magnetic resonance 
spectroscopy (MRS) of CD brain showed 
approximately 3 fold higher NAA in CD 
(Grodd et al., 1990; Wittsack et al., 1996). 
The accumulation of NAA in the brain 
results in an increased urinary NAA in CD. 
Patients with CD have more than 50 fold 
higher urinary NAA (1440±873.3 
μmol/mmol) compared to the normal 
subjects (23.5 ±16.1 μmol/mmol). ASPA 
deficiency resulting NAA accumulation in 
the brain suggests that abnormal NAA 
level contributes to spongiform 
degeneration. 
 
The brain of CD showed swollen 
astrocytes and distorted and elongated 
mitochondria (Adachi et al., 1972; 
Adornato et al., 1972; Luo and Huang, 
1984). Computed tomography (CT) of the 
head or magnetic resonance imaging 
(MRI) of the brain showed white matter 
degeneration in CD (Rushton et al., 1981; 
Brismar et al., 1990). These studies 
suggest that mitochondrial defect is likely 
one of the contributing factors of 
neurodegeneration seen in CD. 
 
ASPA deficiency in the mouse affects the 
central nervous system 
ASPA knockout in the mouse leads to 
vacuolation throughout white matter of the 
brain (Matalon et al., 2000). In contrast, 
spinal cord of the mouse showed severe 
vacuolation in the gray matter than white 
matter (Surendran et al., 2005). These 
studies in the mouse suggest that ASPA 
knockout affects normal development of 
the brain and spinal cord to contribute in 
abnormal function. Lesion in any one of 
these parts of the spinal cord would 
impede functions including walking 
(McKenna et al., 1996). The changes 
observed in the ASPA knockout mouse 
spinal cord suggests that spinal cord 
pathology is one of the important 
contributing factors of behavioral deficit 
seen in CD. 
 
ASPA knockout affects glutamate-
ketoglutarate dehydrogenase complex 
pathway 
ASPA knockout in the mouse reduced the 
levels of potential neurotransmitters, 
glutamate and GABA in the brain 
(Surendran et al., 2003a). During low 
levels of external glutamate, the glutamine 
synthetase pathway is turned on and when 
external glutamate levels are high, the 
oxidative pathway (Tri carboxylic acid 
cycle; via 2-oxoglutarate) is turned on with 
considerable glutamate being consumed 
via the astrocytic malate dehydrogenase 
(McKenna et al., 1996). 
 
The enzyme which reversibly converts 
aspartate to glutamate, aspartate 
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aminotransferase (AAT; EC 2.6.1.1) was 
found to be lower in the brain of ASPA 
knockout mouse (Surendran et al., 2003b) 
(Fig 2). Both neurons and astrocytes 
oxidize glutamate via glutamate 
dehydrogenase (GDH; EC 1.4.1.3), a 
major route for the entry of glutamate 
carbon into the TCA cycle. GDH converts 
glutamate into 2-oxoglutarate or the 
reverse (Rajeswari et al., 1984) and this 
enzyme was also found to be lower in the 
mouse (Surendran et al., 2004b). 
Downregulation of GDH leads to abnormal 
glutamate metabolism to induce 
neurodegeneration via neuroexcitotoxic 
mechanisms (Chokroverty et al., 1984). 
 
 
 
 
Figure 2: Enzymes involved in the aspartate-glutamate-GABA metabolic 
pathway. AAT=Aspartate aminotransferase, PAG=phosphate activated 
glutaminase, GS=glutamine synthase, GAD= glutamic acid decarboxylase, GT= 
GABA transaminase, SSDH= succinic semialdehyde dehydrogenase, GDH= 
glutamate dehydrogenase, KGDH= α-ketoglutarate dehydrogenase. 
 
 
α-Ketoglutarate dehydrogenase complex 
(KGDHC; EC 1.2.4.2, EC 2.3.1.61, and 
EC 1.6.4.3) converts α-ketoglutarate into 
succinyl CoA. Lower levels of KGDHC 
induce caspase 3 to resulting in 
neurodegeneration (Huang et al., 2003). 
The metabolic enzyme activity was found 
to be lower in the brain of ASPA knockout 
mouse (Surendran et al., 2004b). These 
studies suggest that lower levels of 
neurotransmitters and metabolic enzymes 
seen in the ASPA knockout mouse brain 
are likely to contribute to 
neurodegeneration. 
 
Transport of glutamine from astrocytes to 
neurons is important for the synthesis of γ-
aminobutyric acid (GABA).  The 
converted glutamate from glutamine, 
serves as a precursor for GABA (Petroff et 
al., 1999) (Fig 2). GABA is lower in the 
ASPA knockout mouse brain (Surendran et 
al., 2003c) suggests that ASPA deficiency 
hampers inhibitory function of GABA. 
 
While N-acetylaspartylglutamate (NAAG) 
is synthesized in neurons, the enzyme that 
cleaves NAAG to NAA and glutamate (Fig 
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3), carboxypeptidase II is limited to 
astrocytes (Robinson et al., 1987; Stauch et 
al., 1989; Slusher et al., 1990; Williamson 
et al., 1991). In neurons, NAA and 
glutamate are converted into NAAG in the 
presence of N-acetylaspartate-L-glutamate 
ligase (Tyson et al., 1998). NAAG level is 
approximately 20 fold higher in CD 
(Burlina et al., 1994, 1999; Krawczyk et 
al., 2003). Meantime, NAAG was not 
affected in the brain of ASPA knockout 
mouse. Spinal cord neurodegeneration 
resulting NAAG disposal may be one of 
the contributing factors of elevated NAAG 
seen in CD. 
 
 
 
 
Figure 3: NAAG is hydrolyzed into N-acetylaspartic acid and glutamate by 
NAALADase/glutamate carboxypeptidase II. NAA and glutamate are converted 
into NAAG by N-acetylaspartate-L-glutamate ligase. 
 
Therapeutical attempts to recover 
neurodegeneration in CD 
Gene transfer and cell implantation are the 
attempts made to treat neurodegeneration 
seen in CD. ASPA gene transfer to the 
brain of children with CD improved brain 
NAA levels (Leone et al., 2000). MRI 
images in one of the ASPA injected child’s 
subcortical white matter showed 
improvement of signal intensity (Leone et 
al., 2000) suggests that ASPA gene 
transfer improves myelination. 
Adenoassociated virus mediated ASPA 
gene transfer to the brain of ASPA 
knockout mouse, improved spongiform 
degeneration and brain NAA levels 
(Matalon et al., 2003). However the effect 
was close to the injected site. Although 
gene transfer improves neurodegeneration, 
whether the gene transfer affects the entire 
CNS and improves all the events seen in 
CD is to be studied. 
 
Cell therapy is one of the approaches to 
recover the lost enzyme and to replace the 
lost cells. Implantation of neural progenitor 
cells to the knockout mouse brain 
differentiated into oligodendrocytes, the 
ASPA synthesizing cells and fibrous 
astrocytes (Surendran et al., 2004a) 
suggests that neural progenitor cells may 
be used to recover the lost enzyme as well 
as the lost cells in CD. 
 
Conclusion 
ASPA knockout in the mouse affects 
metabolic levels. ASPA knockout not only 
affects the brain but also the spinal cord. 
Whether gene transfer affects all the events 
seen in CD is to be studied. 
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